Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) has announced that its previously approved 1-for-100 reverse stock split will take effect on March 24, 2026, at 4:30 PM Eastern Time. Following this split, the company's common stock will begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026, under the temporary symbol 'ENZND' for a period of 20 trading days. The reverse stock split will consolidate every 100 shares of the company's issued and outstanding common stock into one share, while the par value per share will remain unchanged. No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive a proportional cash payment. This action is part of the company's strategy to facilitate the anticipated merger with Viskase Companies, Inc., which requires additional authorized shares of common stock. The expiration of the exchange offer related to this merger is also set for March 24, 2026, with the closing expected to occur shortly thereafter. Enzon's management believes that this reverse stock split is in the best interests of the company and its stockholders, as it positions the company for future growth and stability.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.